Skip to main content
. Author manuscript; available in PMC: 2019 Jul 1.
Published in final edited form as: J Acquir Immune Defic Syndr. 2018 Jul 1;78(3):348–355. doi: 10.1097/QAI.0000000000001675

Table 1.

Envelope characterization

Env Subject Year of
isolation		 Stage1 Co-receptor
usage		 Co-receptor
prediction		 Accession
number
40061 40061 2009 early FI/II CCR5 CCR5 KY580548
40100 Mj 40100 2010 early FI/II CCR5 CXCR4/CCR5 KY580588
40100 mn 40100 2010 early FI/II CCR5 CXCR4/CCR5 MF622080
356272 AA047 2005 late FI/II CCR5 CXCR4/CCR5 JN944654
427299 AA116 2006 late FI/II CCR5 CCR5 JN944655
620345 AA081 2005 late FI/II CCR5 CXCR4/CCR5 JX12900
703357 AA118 2005 late FI/II CCR5 CCR5 JN944658
816763 AA119 2006 late FI/II CCR5 CXCR4/CCR5 JN944659
434239 AA058 2006 FIII-V CCR5 CXCR4/CCR5 JX447346
731027 AA104 2006 FIII-V CCR5 CCR5 JX447986
816769 AA107 2006 FIII-V CCR5 CCR5 JX448026
TH023 92TH023 1992 C CCR5 CCR5 KU562843
CM244 1990 C CCR5 CCR5 AY13425
CM245 1990 C CCR5 CXCR4/CCR5 JN944662
1

Stages of infection. Early FI/II: Fiebig stage I/II isolated within 7 days after the patient’s first nucleic acid positive test; late FI/II: Fiebig stage I/II; FIII-V: Fiebig stage III-V; C: chronic (after Fiebig stage VI).